Leerink Partnrs Has Pessimistic View of CLOV Q1 Earnings

Clover Health Investments, Corp. (NASDAQ:CLOV) – Stock analysts at Leerink Partnrs decreased their Q1 2025 EPS estimates for shares of Clover Health Investments in a note issued to investors on Sunday, March 2nd. Leerink Partnrs analyst W. Mayo now expects that the company will earn ($0.07) per share for the quarter, down from their prior forecast of ($0.03). The consensus estimate for Clover Health Investments’ current full-year earnings is ($0.12) per share. Leerink Partnrs also issued estimates for Clover Health Investments’ Q2 2025 earnings at $0.00 EPS, Q4 2025 earnings at ($0.13) EPS, FY2025 earnings at ($0.20) EPS, Q1 2026 earnings at ($0.05) EPS, Q2 2026 earnings at $0.03 EPS, Q3 2026 earnings at $0.02 EPS, Q4 2026 earnings at ($0.12) EPS, FY2026 earnings at ($0.12) EPS, FY2027 earnings at ($0.06) EPS, FY2028 earnings at $0.00 EPS and FY2029 earnings at $0.07 EPS.

Several other research analysts have also weighed in on CLOV. Canaccord Genuity Group boosted their price target on Clover Health Investments from $4.20 to $4.50 and gave the stock a “buy” rating in a research report on Monday. Craig Hallum began coverage on shares of Clover Health Investments in a research report on Tuesday, December 17th. They set a “buy” rating and a $6.00 price target on the stock.

Clover Health Investments Stock Performance

CLOV opened at $3.83 on Wednesday. The business’s 50-day simple moving average is $4.07 and its 200 day simple moving average is $3.61. Clover Health Investments has a 52-week low of $0.61 and a 52-week high of $4.87. The firm has a market capitalization of $1.92 billion, a PE ratio of -19.15 and a beta of 2.00.

Hedge Funds Weigh In On Clover Health Investments

A number of institutional investors have recently bought and sold shares of CLOV. Concurrent Investment Advisors LLC bought a new position in shares of Clover Health Investments during the 3rd quarter worth approximately $28,000. Sigma Planning Corp bought a new position in Clover Health Investments during the third quarter worth $29,000. Parallax Volatility Advisers L.P. acquired a new position in shares of Clover Health Investments in the third quarter valued at $38,000. Triumph Capital Management bought a new position in shares of Clover Health Investments in the fourth quarter valued at about $45,000. Finally, Forum Financial Management LP raised its position in shares of Clover Health Investments by 33.8% in the third quarter. Forum Financial Management LP now owns 16,077 shares of the company’s stock valued at $45,000 after purchasing an additional 4,061 shares during the period. Institutional investors and hedge funds own 19.77% of the company’s stock.

Clover Health Investments Company Profile

Clover Health Investments, Corp. provides medicare advantage plans in the United States. It operates through two segments: Insurance and Non-Insurance. It also offers Clover Assistant, a cloud-based software platform, that enables physicians to detect, identify, and manage chronic diseases earlier; and access to data-driven and personalized insights for the patients they treat.